Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carboxylic Acid Metabolite SCHEMBL2119610 | 0.95 | AGTR2 (0.62) | AGTR1AGTR2 | |
| SCHEMBL4657793 | 0.93 | AGTR1 (0.57) | AGTR1AGTR2 | |
| SCHEMBL17750007 | 0.92 | AGTR1 (0.53) | AGTR1AGTR2 | |
| SCHEMBL9327743 | 0.91 | AGTR1 (0.58) | AGTR1AGTR2 | |
| SCHEMBL1904786 | 0.91 | AGTR1 (0.53) | AGTR1AGTR2 | |
| SCHEMBL8063465 | 0.91 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL6891884 | 0.90 | AGTR1 (0.56) | AGTR1AGTR2 | |
| SCHEMBL17653793 | 0.90 | AGTR1 (0.54) | AGTR1AGTR2 | |
| SCHEMBL5037958 | 0.90 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL10053021 | 0.89 | AGTR1 (0.55) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116773693-A | Method for detecting 11 antihypertensive drugs and 1 metabolite in blood by liquid chromatography-tandem mass spectrometry and application of method | 合肥和合医疗科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| US-20230218582-A1 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | STREETERVILLE CAPITAL, LLC | 2023-07-13 | — | — | US | claimed |
| CN-114609287-A | Method for detecting amlodipine, losartan and losartan metabolite thereof in blood plasma by LC-MS (liquid chromatography-mass spectrometry) method | 四川尚锐分析检测有限公司 | 2022-06-10 | — | — | CN | claimed |
| WO-2022076746-A1 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | SCIENTURE, INC. (US) | 2022-04-14 | — | — | WO | claimed |
| CN-111443135-A | Method for determining concentrations of hydrochlorothiazide, losartan and losartan 5-carboxylate in plasma by liquid chromatography-mass spectrometry | 苏州国辰生物科技股份有限公司 | 2020-07-24 | — | — | CN | claimed |
| CN-102802611-B | Pharmaceutical composition containing carboxylosartan and a production method therefor | JIN YANG PHARM CO LTD | 2014-11-12 | — | — | CN | claimed |
| EP-2446879-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CARBOXYLOSARTAN AND A PRODUCTION METHOD THEREFOR | JIN YANG PHARM CO LTD (KR) | 2014-02-12 | — | — | EP | claimed |
| CN-102802611-A | Pharmaceutical composition containing carboxylosartan and a production method therefor | JIN YANG PHARM CO LTD | 2012-11-28 | — | — | CN | claimed |
| EP-2446879-A2 | PHARMACEUTICAL COMPOSITION CONTAINING CARBOXYLOSARTAN AND A PRODUCTION METHOD THEREFOR | Jin Yang Pharm. Co., Ltd. (KR) | 2012-05-02 | — | — | EP | claimed |
| US-20120095067-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CARBOXYLOSARTAN AND A PRODUCTION METHOD THEREFOR | JIN YANG PHARM. CO., LTD. (KR) | 2012-04-19 | — | — | US | claimed |
| US-12605365-B2 | Losartan liquid formulations and methods of use | SCIENTURE, LLC (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250319070-A1 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | STREETERVILLE CAPITAL, LLC | 2025-10-16 | — | — | US | disclosed |
| US-12156869-B2 | Losartan liquid formulations and methods of use | SCIENTURE, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240293371-A9 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | SCIENTURE, LLC | 2024-09-05 | — | — | US | disclosed |
| US-20240156787-A1 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | STREETERVILLE CAPITAL, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-2079451-A1 | COMBINED PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THEORY | Hanall Pharmaceutical Co., Ltd. (KR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008054121-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDES AND ANGIOTENSIN-II-RECEPTOR BLOCKERS | HANALL PHARMACEUTICAL COMPANY. LTD (KR) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008054123-A1 | CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | HANALL PHARMACEUTICAL COMPANY, LTD. (KR) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008044862-A1 | COMBINED PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THEORY | HANALL PHARMACEUTICAL CO., LTD. (KR) | 2008-04-17 | — | — | WO | disclosed |
| CN-1931857-A | Prepn process of 5-losartan carboxylate | UNIV NANJING AERONAUTICS & ASTRONAUTICS (CN) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319070-A1 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | REN, AGTR1, ACE | AGTR1 2/4885AGTR2 5/4885 |
| US-12605365-B2 | Losartan liquid formulations and methods of use | AGT, ACE, REN | AGTR1 5/4885AGTR2 11/4885 |
| US-20240156787-A1 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | REN, AGTR1, ACE | AGTR1 2/4885AGTR2 5/4885 |
| US-20120095067-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CARBOXYLOSARTAN AND A PRODUCTION METHOD THEREFOR | CYP4A11, REN, CYP4F11 | AGTR1 9/4885AGTR2 20/4885 |
| US-20230218582-A1 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | REN, AGTR1, ACE | AGTR1 2/4885AGTR2 5/4885 |
| US-20240293371-A9 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | REN, AGTR1, ACE | AGTR1 2/4885AGTR2 5/4885 |
| US-12156869-B2 | Losartan liquid formulations and methods of use | REN, AGTR1, ACE | AGTR1 2/4885AGTR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.